Resource Summary Report

Generated by ASWG on Sep 18, 2026

Oregon Health and Science University Medicinal Chemistry Core Facility

RRID:SCR_019048
Type: Tool

Proper Citation

Oregon Health and Science University Medicinal Chemistry Core Facility (RRID:SCR_019048)

Resource Information

URL: http://www.ohsu.edu/mcc

Proper Citation: Oregon Health and Science University Medicinal Chemistry Core Facility (RRID:SCR_019048)

Description: Core helps researchers investigate interactions between small molecules and biological systems by providing medicinal chemistry and chemical biology expertise and organic synthesis support.

Synonyms: Oregon Health and Science University OHSU Medicinal Chemistry Core, OHSU Medicinal Chemistry Core

Resource Type: access service resource, core facility, service resource

Keywords: ABRF, USEDit, medicinal chemistry, small molecules interaction, organic synthesis, chemical biology expertise, ABRF, ABRF

Resource Name: Oregon Health and Science University Medicinal Chemistry Core Facility

Resource ID: SCR_019048

Alternate IDs: ABRF_1050

Alternate URLs: https://coremarketplace.org/?FacilityID=1050

Record Creation Time: 20220129T080343+0000

Record Last Update: 20260912T200408+0000

Ratings and Alerts

No rating or validation information has been found for Oregon Health and Science University Medicinal Chemistry Core Facility.

No alerts have been found for Oregon Health and Science University Medicinal Chemistry Core Facility.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at ASWG .

Kim SJ, et al. (2026) Antigenic stimulation in conjunction with cytokine is required for mediating IL-17A production in human MAIT cells. bioRxiv : the preprint server for biology.

Devlin KL, et al. (2026) Chemoproteomic Elucidation of ??-Lactam Drug Targets in Mycobacterium abscessus. ACS infectious diseases, 12(5), 1669.

Bates TA, et al. (2026) An MR1-specific nanobody capable of blocking MR1T cell activation. Journal of immunology (Baltimore, Md. : 1950), 215(6).

Pou S, et al. (2026) Revisiting 2-Substituted-4(1H)-Quinolones for Targeting the Plasmodium falciparum Cytochrome bc1 Complex. Journal of medicinal chemistry, 69(12), 14114.

Kulicke CA, et al. (2026) Mutations outside the MR1 antigen binding groove differentially inhibit presentation of exogenous antigens. The Journal of biological chemistry, 302(4), 111317.

Kain D, et al. (2026) Human neonatal MR1T cells have more diverse TCR repertoires but reduced bacterial recognition than adult MR1T cells. Nature communications.